» Articles » PMID: 9917503

Clinicopathologic Significance of Protein Induced Vitamin K Absence or Antagonist II and Alpha-fetoprotein in Hepatocellular Carcinoma

Overview
Journal Int J Oncol
Specialty Oncology
Date 1999 Jan 26
PMID 9917503
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Protein induced vitamin K absence or antagonist II (PIVKA-II) and alpha-fetoprotein (AFP) have been considered useful serum markers of hepatocellular carcinoma (HCC). In this study, we examined the clinicopathologic significance of these tumour markers in patients with HCCs by measuring their serum levels and performing immunohistochemistry. We studied 349 Japanese patients with HCCs. Their serum PIVKA-II and AFP levels were determined by enzyme immunoassay before treatment. We examined the correlations between serum PIVKA-II and AFP levels and tumour size, presence of satellite nodules, histologic HCC grade, and concomitant liver diseases and subjected tumour tissues to immunohistochemical staining to detect PIVKA-II and AFP expression. The serum PIVKA-II levels of patients with poorly differentiated HCCs were significantly higher than those of patients with well and moderately differentiated HCCs (p<0.05) and they were higher in HCC patients with than without satellite nodules. The serum AFP levels were influenced significantly by concomitant liver diseases, but not by the other factors. Immunohistochemical staining revealed the PIVKA-II expression levels of poorly differentiated HCCs were higher than those of well and moderately differentiated HCCs (p<0.05). Some HCC cells were PIVKA-II-positive, others were AFP-positive, and some expressed both. The serum PIVKA-II concentration was a better indicator of HCC than AFP, as it was not influenced by concomitant liver diseases. The presence of PIVKA-II in serum correlated with the presence of satellite nodules and the histologic HCC grade, a result concordant with the immunohistochemical findings.

Citing Articles

Vitamins as Possible Cancer Biomarkers: Significance and Limitations.

Venturelli S, Leischner C, Helling T, Burkard M, Marongiu L Nutrients. 2021; 13(11).

PMID: 34836171 PMC: 8622959. DOI: 10.3390/nu13113914.


Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma.

Dong M, Chen Z, Li X, Li X, Wen J, Lin Q Oncol Lett. 2017; 14(5):6277-6284.

PMID: 29113278 PMC: 5661440. DOI: 10.3892/ol.2017.6938.


Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.

Berretta M, Cavaliere C, Alessandrini L, Stanzione B, Facchini G, Balestreri L Oncotarget. 2017; 8(8):14192-14220.

PMID: 28077782 PMC: 5355172. DOI: 10.18632/oncotarget.13929.


Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma.

Li J, Cheng Z, Liu Y, Yan Z, Wang K, Wu D Oncotarget. 2015; 6(11):9551-63.

PMID: 25871387 PMC: 4496238. DOI: 10.18632/oncotarget.3314.


The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.

Kang K, Kim J, Kang S, Lee B, Seo Y, Yim H Gut Liver. 2014; 9(2):224-30.

PMID: 25473073 PMC: 4351030. DOI: 10.5009/gnl14047.